Nascent Biotech Inc. (NBIO)

OTCMKTS: NBIO · Delayed Price · USD
0.0545 -0.0005 (-0.91%)
Jan 21, 2022 4:00 PM EST - Market closed
Market Cap5.87M
Revenue (ttm)750,000
Net Income (ttm)-278,821
Shares Out107.73M
EPS (ttm)-0.01
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,000
Open0.0545
Previous Close0.0550
Day's Range0.0545 - 0.0545
52-Week Range0.0490 - 0.1595
Beta-2.38
Analystsn/a
Price Targetn/a
Earnings Daten/a

About NBIO

Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a monoclonal antibody to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as lung and breast cancer metastases to the brain; and pancreatic cancer. The company is based in Vero Beach, Florida.

IndustryBiotechnology
Employees4
Stock ExchangeOTCMKTS
Ticker SymbolNBIO
Full Company Profile

News

Nascent Successfully Completes 2nd Cohort Dosing in Key Phase 1 Metastatic Brain Cancer Trial

VERO BEACH, FL / ACCESSWIRE / January 11, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of...

1 week ago - Accesswire

Nascent Biotech and Manhattan BioSolutions Announce Promising Prelim/Preclinical Results in BCG-Based COVID-19 Vaccin...

SAN DIEGO, CA / ACCESSWIRE / July 13, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a biotechnology company pioneering innovative medicines to overcome diff...

6 months ago - Accesswire

Marble Arch Research Publishes Analyst Research Report on Nascent Biotech

VERO BEACH, FL / ACCESSWIRE / June 15, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of mo...

7 months ago - Accesswire

Nascent Biotech Commencing Enrollment of Second Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer

SAN DIEGO, CA / ACCESSWIRE / June 8, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of mono...

7 months ago - Accesswire

Nascent Biotech and BioRay Pharmaceutical Announce $5,000,000 Exclusive License Agreement for Development and Commerc...

TAIZHOU, ZHEJIANG, CHINA & SAN DIEGO, CA / ACCESSWIRE / May 19, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) and BioRay Pharmaceutical Ltd., today announced that Nascent Biotech ("Nascent" or the "Company"...

8 months ago - Accesswire

Nascent Biotech Continues Anti-Dilution Campaign with Preemptive Settlement of Outstanding Convertible Note

SAN DIEGO, CA / ACCESSWIRE / May 4, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of monoc...

8 months ago - Accesswire

Nascent Biotech Announces Pre-emptive Elimination of Significant Tranche of Convertible Debt

SAN DIEGO, CA / ACCESSWIRE / April 26, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of mo...

8 months ago - Accesswire

Nascent Biotech Announces Initial Dosing Underway in Phase 1 Human Trial for Primary and Metastatic Brain Cancer

SAN DIEGO, CA / ACCESSWIRE / March 31, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech," "Nascent," or the "Company"), a clinical-stage biotechnology company pioneering the development of mo...

9 months ago - Accesswire

Nascent Biotech Opens Phase 1 Human Trial to Evaluate Pritumumab as Treatment Option for Primary and Metastatic Brain...

SAN DIEGO, CA / ACCESSWIRE / March 24, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of mo...

9 months ago - Accesswire

Nascent Biotech Earns US Patent for Crossing Blood-Brain Barrier

SAN DIEGO, CA / ACCESSWIRE / March 2, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of mon...

10 months ago - Accesswire

Nascent Biotech Gains On Encouraging Pritumumab Data From Preclinical Studies

Nascent Biotech Inc (OTCMKTS: NBIO) has announced the publication of promising in-vitro study results from its pritumumab (PTB) research collaboration with Syracuse University, validating the potential ...

11 months ago - Benzinga